JAZZ - Jazz Pharmaceuticals Non-GAAP EPS of $5.17 beats by $0.50 revenue of $940.65M in-line
- Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q3 Non-GAAP EPS of $5.17 beats by $0.50 .
- Revenue of $940.65M (+12.2% Y/Y) in-line.
- FY2022 Outlook : Raising the mid-point of 2022 total revenue guidance to $3.65B driven by increases in the guidance mid-point for both our Neuroscience and Oncology therapeutic areas vs. consensus of $3.64B; Adjusted EPS between $17.20 to $17.85 vs. consensus of $17.30.
For further details see:
Jazz Pharmaceuticals Non-GAAP EPS of $5.17 beats by $0.50, revenue of $940.65M in-line